Clinical trial · Observational
SERum-bank for PANcreatic Cancer
NCT04374175CI-TRIAL-00087358SERPANrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is about pancreatic cancer. If the diagnostic cancer is done at an early stage (\<2cm), the chances of recovery are very good. But the main problem is there is not any detections means for this cancer. Sadly, when there is a cancer diagnostic , it's already too late in the majority of cases, because the cancer is in an advanced case. Today, there is no any effective means of detection... Blood markers can be a simple means of early detection
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma | Adenocarcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sample | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Adenocarcinoma group
- description
- Patients with Adenocarcinoma will be included. They will have blood sample at the inclusion visit and at 3 months, 6 months, 9 months and 12 months after.
- interventionNames
- Biological: Blood sample
- label
- Control group
- description
- Patient with no adenocarcinoma will be included. They will have blood sample at the inclusion visit.
- interventionNames
- Biological: Blood sample
Primary outcomes (1)
- measure
- Serum adiponectin concentration
- timeFrame
- Months : 0
- description
- Measure by blood sample result Serum adiponectin concentration threshold for which the specificity will be 100% for the diagnosis of pancreatic cancer with a sensitivity of 80%.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
ADENOCARCINOMA GROUP Inclusion Criteria: * Documented adenocarcinoma (cytology / anatomopathology), all stages, except if the tumor is immediately resectable and does not require preoperative cytological evidence. In this case, the inclusion and the first collection of the sero bank is done preoperatively. The diagnostic confirmation will therefore be made post-operatively at the risk of being excluded in the event of a different diagnosis. * At the start of treatment (before surgery / 1st course of chemotherapy) * Age ≥ 18 years * Patient affiliated or entitled to a social security system Exclusion Criteria: * Patient refusal * Acute renal failure * Child-Pugh B or C cirrhosis * Patient under guardianship or curators * Other synchronous cancer or history of cancer \<5 years * Language barrier CONTROL GROUP Inclusion Criteria: * Age ≥ 40 years * Patient affiliated or entitled to a social security system * Digestive endoscopy for any reason other than cancer or chronic inflammatory bowel disease Exclusion Criteria: * Patient refusal * Acute renal failure * Child-Pugh B or C cirrhosis * Patient under guardianship or curators * Other synchronous cancer or history of cancer \<5 years
References
Publications (0)
Data not yet available
No reference posted for this study.